Kunwei Technology (Krinwave) Raises RMB 400M Series B Led by HSG

Kunwei Technology, known internationally as Krinwave, has raised RMB 400 million in a Series B round led by HSG (HongShan Capital/Sequoia China). The round was announced on October 9, 2026, and included participation from Tencent, Sherpa Healthcare Partners, and XVC.

What Krinwave Does

Krinwave is a Shenzhen-based medical-imaging company founded in 2019. It develops super-resolution ultrasound systems built on a full-stack acoustic spatial intelligence platform spanning probes, imaging hardware, and its kOS ultrasound operating system.

The company's core technical approach combines low-frequency transcranial ultrasound with GPU-computed beamforming. Multiple outlets have described Krinwave as the only company worldwide achieving non-invasive, high-resolution imaging of the brain through the skull. That capability has direct applications in stroke, neurocritical care, and neurodegenerative disease.

Regulatory and Commercial Status

Krinwave's cranial ultrasound products hold Chinese NMPA and EU CE-MDR registrations, with US FDA certification in progress. Since launching commercialization at the end of 2025, the company reports completed clinical validation and deployments at leading hospitals in China and overseas.

Funding Details

Round: Series B
Amount: RMB 400 million
Date: October 9, 2026
Lead investor: HSG (HongShan Capital/Sequoia China)
Participating investors: Tencent, Sherpa Healthcare Partners, XVC

Why the Round Matters

Krinwave sits at the intersection of two trends that have attracted significant strategic capital: advanced medical imaging hardware and AI-adjacent computational platforms. The company's full-stack approach — probes, hardware, and operating system — means it controls the entire signal path from acquisition through computation, rather than assembling components from third parties.

Transcranial imaging through the skull is a longstanding technical challenge in ultrasound, because bone scatters and attenuates acoustic signals. A low-frequency approach combined with GPU-computed beamforming is the mechanism Krinwave uses to address that problem. If the company's claim of being the only firm worldwide to achieve non-invasive, high-resolution brain imaging through the skull holds, it represents a defensible technical position in a large clinical market.

The investor syndicate reflects a mix of healthcare-focused and general technology capital. HSG leads, with Sherpa Healthcare Partners — a dedicated healthcare fund — participating alongside Tencent and XVC.

Clinical Relevance

The target applications are areas where rapid, non-invasive brain imaging has clear clinical value:

Stroke: Time-critical diagnosis where non-invasive imaging could accelerate treatment decisions
Neurocritical care: Continuous or repeated monitoring of critically ill patients
Neurodegenerative disease: Longitudinal imaging where non-invasive methods are preferable to alternatives

What to Watch

Progress on US FDA certification
Expansion of hospital deployments beyond the initial clinical validation sites in China and overseas
Adoption of the kOS ultrasound operating system as a platform, independent of Krinwave's own hardware
Competitive dynamics in transcranial ultrasound imaging

Summary

Kunwei Technology (Krinwave) has raised RMB 400 million in a Series B round led by HSG (HongShan Capital/Sequoia China), with Tencent, Sherpa Healthcare Partners, and XVC participating. The Shenzhen company, founded in 2019, builds super-resolution ultrasound systems on a full-stack acoustic spatial intelligence platform and is described as the only company worldwide achieving non-invasive, high-resolution brain imaging through the skull. Its cranial ultrasound products hold NMPA and CE-MDR registrations, with FDA certification in progress.